Preparing the structured Flagship evidence library.
Flagship peptide evidence profile
This research library contains structured AI-assisted scientific review. AI-assisted review is not accountable human scientific approval. Inclusion here does not constitute publication approval, clinical guidance, efficacy proof, or automatic promotion of a scientific conclusion.
global evidence atlas
This is a deduplicated PubMed screening registry—not a claim that every mention directly proves efficacy or safety. Machine proposals remain visibly separate from governed human appraisal.
500 matching records · ranked 2026-09-18
Page 1 of 20
Expert opinion on drug safety · 2026 Jun · PMID 41200927 · DOI 10.1080/14740338.2025.2586703
Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness · Mechanism and pharmacology
Cardiovascular diabetology · 2026 Feb 27 · PMID 41761267 · DOI 10.1186/s12933-026-03113-3
Type 2 diabetes and glycemia · Cardiovascular outcomes · Comparative effectiveness · Mechanism and pharmacology
Obesity (Silver Spring, Md.) · 2026 Jun · PMID 41936548 · DOI 10.1002/oby.70169
Weight loss and obesity · Type 2 diabetes and glycemia · Comparative effectiveness · Mechanism and pharmacology
Postgraduate medical journal · 2026 May 20 · PMID 41536268 · DOI 10.1093/postmj/qgaf238
Weight loss and obesity · Type 2 diabetes and glycemia · Real-world outcomes
Advances in therapy · 2026 May · PMID 41820778 · DOI 10.1007/s12325-026-03523-5
Weight loss and obesity · Safety and tolerability · Comparative effectiveness
Diabetes, obesity & metabolism · 2026 Jul · PMID 42050884 · DOI 10.1111/dom.70773
Weight loss and obesity · Safety and tolerability · Comparative effectiveness
Diabetes, obesity & metabolism · 2026 Aug · PMID 42115707 · DOI 10.1111/dom.70859
Type 2 diabetes and glycemia · Cardiovascular outcomes · Comparative effectiveness
Cureus · 2026 May · PMID 42326175 · DOI 10.7759/cureus.109350
Weight loss and obesity · Type 2 diabetes and glycemia · Cardiovascular outcomes
Diabetes research and clinical practice · 2026 Sep · PMID 42442557 · DOI 10.1016/j.diabres.2026.113431
Weight loss and obesity · Type 2 diabetes and glycemia · Cardiovascular outcomes
Journal of diabetes · 2026 Feb · PMID 41664890 · DOI 10.1111/1753-0407.70192
Weight loss and obesity · Comparative effectiveness
Disease-a-month : DM · 2026 Jun · PMID 41862384 · DOI 10.1016/j.disamonth.2026.102099
Heart failure · Safety and tolerability
BMC medicine · 2026 Mar 27 · PMID 41896878 · DOI 10.1186/s12916-026-04824-w
Cardiovascular outcomes · Safety and tolerability
Clinical obesity · 2026 Oct · PMID 42670242 · DOI 10.1111/cob.70111
Weight loss and obesity · Comparative effectiveness
World journal of diabetes · 2025 Feb 15 · PMID 39959269 · DOI 10.4239/wjd.v16.i2.101282
Type 2 diabetes and glycemia · Kidney outcomes · Safety and tolerability
Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025 Jun · PMID 40214900 · DOI 10.1007/s13300-025-01728-5
Type 2 diabetes and glycemia · Safety and tolerability · Comparative effectiveness
Pharmaceuticals (Basel, Switzerland) · 2025 Apr 30 · PMID 40430487 · DOI 10.3390/ph18050668
Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability
Journal of obesity · 2025 · PMID 40746703 · DOI 10.1155/jobe/3442754
Weight loss and obesity · Comparative effectiveness · Mechanism and pharmacology
Diabetes/metabolism research and reviews · 2025 Oct · PMID 41100405 · DOI 10.1002/dmrr.70097
Weight loss and obesity · Type 2 diabetes and glycemia · Heart failure
TouchREVIEWS in endocrinology · 2024 Oct · PMID 39526060 · DOI 10.17925/EE.2024.20.2.10
Weight loss and obesity · Type 2 diabetes and glycemia · Safety and tolerability · Mechanism and pharmacology
Reviews in endocrine & metabolic disorders · 2026 Feb · PMID 41032183 · DOI 10.1007/s11154-025-09991-4
Mechanism and pharmacology
Frontiers in pharmacology · 2026 · PMID 41908834 · DOI 10.3389/fphar.2026.1735987
Safety and tolerability
Frontiers in pharmacology · 2026 · PMID 42137317 · DOI 10.3389/fphar.2026.1834664
Safety and tolerability
Endocrine · 2026 Aug 15 · PMID 42603240 · DOI 10.1007/s12020-026-04757-7
Cardiovascular outcomes
Journal of the American Heart Association · 2026 Sep 15 · PMID 42714458 · DOI 10.1161/JAHA.125.044249
Weight loss and obesity
Journal of diabetes investigation · 2025 Jan · PMID 39569606 · DOI 10.1111/jdi.14340
Weight loss and obesity · Type 2 diabetes and glycemia
Tirzepatide · PMID 41406444
Primary cardiovascular events occurred in 12.2% of the tirzepatide group and 13.1% of the dulaglutide group.
Tirzepatide · PMID 39536238
At 176 weeks, mean weight changes were -12.3%, -18.7%, and -19.7% with tirzepatide 5, 10, and 15 mg, respectively, versus -1.3% with placebo.
Tirzepatide · PMID 38912654
Estimated treatment differences in AHI were -20.0 events per hour in trial 1 and -23.8 events per hour in trial 2 versus placebo.
Tirzepatide · PMID 35658024
Mean weight change at week 72 was -15.0%, -19.5%, and -20.9% with tirzepatide 5, 10, and 15 mg versus -3.1% with placebo.
Tirzepatide · PMID 38613667
In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively.
Tirzepatide · PMID 38976257
On-treatment weight change in a propensity score-matched population, assessed as hazard of achieving 5% or greater, 10% or greater, and 15% or greater weight loss, and percentage change in weight at 3, 6, and 12 months.